Article discusses the impact of diagnosis to treatment interval in clinical trials for DLBCL.
Home / Resource Library / Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials